KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2016 - 2026)

Teva Pharmaceutical Industries filings provide 14 years of Shares Outstanding readings, the most recent being $1.3 billion for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 1.44% to $1.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 billion, a 1.44% increase, with the full-year FY2025 number at $1.3 billion, up 4.67% from a year prior.
  • Shares Outstanding hit $1.3 billion in Q1 2026 for Teva Pharmaceutical Industries, up from $1.3 billion in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $1.3 billion in Q1 2026 to a low of $1.2 billion in Q1 2022.
  • Median Shares Outstanding over the past 5 years was $1.2 billion (2024), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Shares Outstanding: rose 0.58% in 2022 and later grew 1.44% in 2026.
  • Teva Pharmaceutical Industries' Shares Outstanding stood at $1.2 billion in 2022, then grew by 0.82% to $1.2 billion in 2023, then grew by 1.06% to $1.2 billion in 2024, then rose by 1.29% to $1.3 billion in 2025, then increased by 1.19% to $1.3 billion in 2026.
  • The last three reported values for Shares Outstanding were $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025) per Business Quant data.